Peripheral blood CD4+ T cells (%) and NK cells (%) measured at week 3 post-treatment serve as accurate and convenient biomarkers for predicting treatment efficacy and long-term outcomes (PFS and OS) in advanced HCC patients undergoing ICI immunotherapy. Here, CD4 is linked to hepatocellular carcinoma.